Beta Bionics, Inc. (BBNX) Liabilities and Shareholders Equity (2023 - 2026)

Beta Bionics (BBNX) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $304.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 9.94% year-over-year to $304.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 165.18% YoY) and the FY2025 annual result came in at $328.7 million, up 119.68% from the prior year.
• Liabilities and Shareholders Equity retreated to $304.4 million in Q1 2026 per BBNX's latest filing, from $328.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $338.0 million in Q1 2025, with the low at $110.0 million in Q4 2023.
• Average Liabilities and Shareholders Equity over 4 years is $270.1 million, with a median of $328.7 million recorded in 2025.
• Year-over-year, Liabilities and Shareholders Equity surged 119.68% in 2025 and decreased 9.94% in 2026.
• Beta Bionics' Liabilities and Shareholders Equity stood at $110.0 million in 2023, then soared by 35.99% to $149.6 million in 2024, then surged by 119.68% to $328.7 million in 2025, then decreased by 7.4% to $304.4 million in 2026.
• Business Quant data shows BBNX's Liabilities and Shareholders Equity at $304.4 million in Q1 2026, $328.7 million in Q4 2025, and $330.0 million in Q3 2025.